After years of facing new developments related to tariffs and the trade war with China, and CFIUS (The Committee on Foreign Investment in the United States), boards and management teams were confronted with the global pandemic, which introduced new challenges related to global health, vaccine development and distribution, and supply chain disruption as the global economy begins to grow again. All of these areas have increased deal scrutiny and operational complexity in dealing with China, raising the stakes for careful management of international operations and cross-border transactions. The shifting political winds in the U.S. and China also complicate the landscape. What are some of the more serious national security and privacy implications of transactions involving data usage, and what kinds of data are most sensitive? Are risks with China-related transactions able to be mitigated over the long term? Will the Biden Administration pursue a similar strategy with China as the Trump Administration? What are some solutions that companies have put in place to push transactions forward? How will tariffs, the pandemic, and the relationship between China and the U.S. going forward affect the supply chain and the market? This panel will discuss how and why the regulatory landscape has evolved so significantly in the last few years and what best practices boards can deploy to help their companies navigate this complex environment and mitigate risk.